4. Tubulo-interstitial Damage (TID)
Definition: A heterogeneous group of inflammatory and non-inflammatory diseases which primarily affect the tubulo-interstitial space.
Displaying 1-3 of 3 results.
4.1. ATN (so-called acute tubulonecrosis)
Definition:
Morphological lesions of the tubulo-interstitial space accompanied by acute renal failure.
4.2. Interstitial (non destructive) nephritis
Definition:
Interstial inflammation with tubulitis but without overt destruction of the parenchyma
4.3 Chronic unspecific tubulo-interstitial damage (CID)
Definition:
Damage mainly of the tubulo-interstitial space without significant involvement of the vessels and glomeruli
Drugs:
- A01 Stomatological preparations
- A02 Drugs for acid related disorders
- C02 Antihypertensives
- C03 Diuretics
- J01 Antibacterials for systemic use
- amoxicillin
- azithromycin
- azlocillin
- aztreonam
- bacitracin
- Beta-lactamase resistant penicillins
- Beta-lactamase sensitive penicillins
- carbenicillin
- cefalexin
- cefaloridine
- cefalotin
- cefapirin
- cefepime
- cefradine
- ceftriaxone
- ciprofloxacin
- clarithromycin
- First-generation cephalosporins
- Fluoroquinolones
- Glycopeptide antibacterials
- Imidazole derivatives
- lincomycin
- Lincosamides
- Macrolides
- meticillin
- mezlocillin
- moxifloxacin
- Nitrofuran derivatives
- norfloxacin
- ofloxacin
- Other aminoglycosides
- Other quinolones
- piperacillin
- piromidic acid
- Polymyxins
- Quinolone antibacterials
- Second-generation cephalosporins
- sulfadiazine
- sulfamethoxazole
- teicoplanin
- telithromycin
- Third-generation cephalosporins
- trimethoprim
- J04 Antimycobacterials
- J05 Antivirals for systemic use
- N02 Analgesics
- N03 Antiepileptics
- Other Drugs (119 from 210)
- Ace inhibitors, plain*
- acetazolamide
- Acetic acid derivatives and related substances
- aciclovir
- adalimumab
- ajmaline
- allopurinol
- amfetamine
- amlodipine
- amphotericin B
- ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
- azapropazone
- azathioprine
- Barbiturates, plain
- Bismuth preparations
- Bisphosphonates*
- bortezomib
- caffeine
- calcifediol
- Calcineurin inhibitors*
- canagliflozin
- captopril
- carbimazole
- carboplatin
- celecoxib
- chlorpropamide
- ciclosporin
- cisplatin
- clofibrate
- clozapine
- cocaine
- colistin
- Contrast media
- copper sulfate
- Coxibs
- cyamemazine
- cytarabine
- dextran
- diazepam
- diclofenac
- diltiazem
- doxepin
- Drugs for constipation*
- emicizumab
- Ethylene glycol
- everolimus
- exenatide
- fenofibrate
- fenoprofen
- fenoverine
- gelatin agents
- Gold preparations*
- griseofulvin
- halothane
- HMG CoA reductase inhibitors
- hydroxyethylstarch
- ibuprofen
- ibuprofen
- ibuprofen
- ibuprofen
- ifosfamide*
- immunoglobulins, normal human, for intravascular adm.*
- Interferons
- Interleukins
- inulin and other polyfructosans
- ketoconazole
- ketoprofen
- ketorolac
- lisinopril
- Lithium*
- mannitol*
- mefenamic acid*
- mercury, metallic
- mesalazine*
- methadone
- methotrexate
- naproxen*
- naproxen
- nicergoline
- niflumic acid
- nivolumab
- octreotide*
- oxaliplatin
- Oxicams
- Phenothiazines with aliphatic side-chain
- phentermine
- phenylbutazone
- phenylpropanolamine
- Platinum compounds
- plicamycin
- povidone-iodine
- Preparations increasing uric acid excretion
- probenecid
- Propionic acid derivatives
- propranolol
- propylthiouracil
- Quinine and derivatives
- rofecoxib
- sirolimus*
- sodium phosphate
- sodium phosphate
- Sodium-glucose co-transporter 2 (SGLT2) inhibitors
- sorbitol
- sorbitol
- streptokinase
- sulfasalazine
- sulfinpyrazone
- sulindac
- sunitinib
- suprofen
- tacrolimus
- Tetracycline and derivatives
- ticlopidine
- tolmetin
- vancomycin
- vancomycin
- Vitamin D and analogues*
- warfarin
- zomepirac
References: